Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 32, 2009, Pages 13594-13599

  Blurton Jones, Mathew ^a   Kitazawa, Masashi ^a   Martinez Coria, Hilda ^a   Castello, Nicholas A ^a   Müller, Franz Josef ^b,c   Loring, Jeanne F ^b   Yamasaki, Tritia R ^a   Poon, Wayne W ^a   Green, Kim N ^a   LaFerla, Frank M ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Zentrum fur Integrative Psychiatrie   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Beta amyloid; Memory; Neurotrophin; Synapse; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL RENEWAL; CHEMOTAXIS; COGNITION; COGNITIVE DEFECT; HIPPOCAMPUS; LOSS OF FUNCTION MUTATION; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STEREOTACTIC PROCEDURE; SYNAPTIC POTENTIAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTAXIS; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; MICE; MICE, TRANSGENIC; MULTIPOTENT STEM CELLS; NEURONS; OLIGODENDROGLIA; SENILE PLAQUES; STEM CELL TRANSPLANTATION; STEM CELLS; SYNAPSES; TAU PROTEINS;

MUS; MUS MUSCULUS;

EID: 69449091994     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901402106     Document Type: Article

References (33)

1. Ebert AD, Beres AJ, Barber AE, Svendsen CN (2008) Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol 209:213-223.
2. Lu P, Jones LL, Snyder EY, Tuszynski MH (2003) Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol 181(2):115-129. (Pubitemid 36629234)
3. Park KI, et al. (2006) Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: Evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic-ischemic brain injury. Exp Neurol 199(1):179-190.
4. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45(5):675-688. (Pubitemid 40320703)
5. Oddo S, et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39(3):409-421. (Pubitemid 36937044)
6. Mizumoto H, Mizumoto K, Shatos MA, Klassen H, Young MJ (2003) Retinal transplantation of neural progenitor cells derived from the brain of GFP transgenic mice. Vision Res 43(16):1699-1708. (Pubitemid 36733559)
7. Yamasaki TR, et al. (2007) Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 27:11925-11933.
8. Lee JP, et al. (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nature Med 13:439-447.
9. Imitola J, et al. (2004) Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA 101:18117-18122. (Pubitemid 40054083)
10. Kuhn HG, Dickinson-Anson H, Gage FH (1996) Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. J Neurosci 16:2027-2033. (Pubitemid 26144015)
11. Schenk D, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400:173-177. (Pubitemid 29327547)
12. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans. Rejuvenation Res 9:77-84.
13. Oddo S, et al. (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281:39413-39423. (Pubitemid 46041901)
14. Roberson ED, et al. (2007) Reducing endogenous tau ameliorates amyloid betainduced deficits in an Alzheimer's disease mouse model. Science 316:750-754.
15. Santacruz K, et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-481. (Pubitemid 40994688)
16. Walsh DM, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
17. Kayed R, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489. (Pubitemid 36444329)
18. Kayed R, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2:18. (Pubitemid 350209643)
19. Terry RD, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580.
20. Lacor PN, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796-807.
21. Mucke L, et al. (2000) High-level neuronal expression of abeta 1-42 in wild-typehuman amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058. (Pubitemid 30365675)
22. Heldt SA, Stanek L, Chhatwal JP, Ressler KJ (2007) Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 12:656-670. (Pubitemid 46998249)
23. Kamei N, et al. (2007) BDNF, NT-3, and NGF released from transplanted neural progenitor cells promote corticospinal axon growth in organotypic cocultures. Spine 32:1272-1278. (Pubitemid 46791444)
24. Taylor AM, et al. (2005) A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods 2(8):599-605.
25. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88:1337-1342. (Pubitemid 28402270)
26. Kemppainen NM, et al. (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603-1606. (Pubitemid 46717985)
27. Muller FJ, Snyder EY, Loring JF (2006) Gene therapy: Can neural stem cells deliver? Nat Rev Neurosci 7:75-84. (Pubitemid 41828933)
28. Martino G, Pluchino S (2006) The therapeutic potential of neural stem cells. Nat Rev Neurosci 7:395-406.
29. Redmond DE, Jr, et al. (2007) Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci USA 104(29):12175-12180.
30. Laske C, et al. (2006) Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 113:1217-1224. (Pubitemid 44291016)
31. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 93:1412-1421. (Pubitemid 40853264)
32. Garzon DJ, Fahnestock M (2007) Oligomeric amyloid decreases basal levels of brainderived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27:2628-2635.
33. Nagahara AH, et al. (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15:331-337.